文献速递心脑血管急症重症综合管理与镇静镇痛

心源性休克患者危重症相关皮质类固醇不足:患病率与预后作用

Critical Illness-Related Corticosteroid Insufficiency in Cardiogenic Shock Patients: Prevalence and Prognostic Role.
PubMed 文献 · Shock · 2018-01-01
一句话结论单中心前瞻性研究显示,心源性休克患者危重症相关皮质类固醇不足患病率42%(2017共识标准)或32%(2016心源性休克阈值),但均与90天死亡率无关。

该单中心前瞻性观察研究纳入79例心源性休克患者,排除院外心脏骤停、脓毒症、正在使用皮质类固醇及依托咪酯者。入院24小时内行250 μg促肾上腺皮质激素刺激试验,分别按2017共识定义(基础总皮质醇<10 μg/dL或Δ皮质醇<9 μg/dL)和2016心源性休克预后阈值(基础总皮质醇>29 μg/dL且Δ皮质醇<17 μg/dL)判定危重症相关皮质类固醇不足。总体90天死亡率43%,两种标准下患病率分别为42%和32%,但无论采用哪种阈值,皮质类固醇不足均非90天死亡率的独立相关因素。

要点

  • 心源性休克患者中危重症相关皮质类固醇不足常见:2017共识标准患病率42%,2016心源性休克阈值患病率32%。
  • 该研究总体90天死亡率为43%。
  • 无论采用2017共识定义还是2016心源性休克阈值,皮质类固醇不足均非90天死亡率的独立相关因素。
  • 研究为单中心前瞻性观察研究,纳入79例心源性休克患者,排除院外心脏骤停、脓毒症、正在使用皮质类固醇及依托咪酯者。

适用人群与场景

  • 纳入所有心源性休克患者,共79例连续入住重症监护室的患者。
  • 排除标准:院外心脏骤停、脓毒症、正在使用皮质类固醇治疗、使用依托咪酯的患者。

诊断标准与关键阈值

  • 2017共识定义:基础总皮质醇<10 μg/dL或促肾上腺皮质激素刺激后Δ皮质醇(T60-T0)<9 μg/dL。
  • 2016年发表的心源性休克患者预后最差阈值:基础总皮质醇>29 μg/dL且Δ皮质醇(T60-T0)<17 μg/dL。

处置流程与药物剂量

  • 入院24小时内行短促肾上腺皮质激素刺激试验:给予250 μg促肾上腺皮质激素(cosyntropin),测定给药前(T0)和给药后60分钟(T60)血清皮质醇水平。

研究设计与关键结果

  • 单中心前瞻性观察研究,为期3年,纳入79例心源性休克患者。
  • 总体90天死亡率为43%。
  • 按2017共识定义,42%的患者存在危重症相关皮质类固醇不足;按2016心源性休克阈值,32%的患者存在。
  • 无论采用哪种阈值,危重症相关皮质类固醇不足均不是90天死亡率的独立相关因素。

证据类型、等级与局限

  • 证据类型:单中心前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示心源性休克患者中危重症相关皮质类固醇不足常见(42%或32%),但未显示其与90天死亡率独立相关。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cardiogenic shock shares with septic shock common hemodynamic features, inflammatory patterns, and most likely similar complications such as critical illness-related corticosteroid insufficiency. The aim of this study was to evaluate the prevalence of critical illness-related corticosteroid insufficiency in cardiogenic shock patients and to secondarily assess its prognostic value on 90-day mortality.

METHODS: A single-center prospective observational study conducted over a 3-year period and including all patients with cardiogenic shock. Main exclusion criteria were patients with prior cardiac arrest, sepsis, ongoing corticosteroid therapy, and etomidate administration. A short corticotropin test was performed in the first 24 h following admission. Serum cortisol levels were measured before (T0) and 60 min (T60) after administration of 250 μg of cosyntropin. Critical illness-related corticosteroid insufficiency was defined according to the 2017 consensus definition (basal total cortisol<10 μg·dL or a delta cortisol T60-T0<9 μg·dL) as well as the thresholds published in 2016 in cardiogenic shock patients associated with worst prognosis (basal total cortisol>29 μg·dL and delta cortisol T60-T0<17 μg·dL).

RESULTS: Seventy-nine consecutive patients hospitalized in intensive care for cardiogenic shock met the inclusion criteria. Overall mortality was 43% at day 90. Forty-two percent had critical illness-related corticosteroid insufficiency using the 2017 consensus definition and 32% using the 2016 cardiogenic shock thresholds. Presence of critical illness-related corticosteroid insufficiency was not an independent factor associated with 90-day mortality irrespective of the thresholds used.

CONCLUSION: Critical illness-related corticosteroid insufficiency is a frequent occurrence in medical cardiogenic shock. However, in this study, such insufficiency was not associated with prognosis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Ducrocq N, Biferi P, Girerd N, et al. Critical Illness-Related Corticosteroid Insufficiency in Cardiogenic Shock Patients: Prevalence and Prognostic Role. Shock. 2018. PMID: 29280926. doi:10.1097/SHK.0000000000001090

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。